LUB006

LUB006 (also known as QLS2404) is a novel, clinical-stage recombinant antibody fusion protein designed to simultaneously target the type I interferon (IFN-1) and BAFF/APRIL pathways. Developed by Qilu Pharmaceutical, the molecule is constructed by fusing an engineered transmembrane activator and CAML interactor (TACI) domain to an anti-interferon alpha/beta receptor subunit 1 (IFNAR1) monoclonal antibody. By dual-pathway inhibition, LUB006 blocks IFNAR1 signaling (similar to anifrolumab) and neutralizes both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) (similar to telitacicept and povetacicept). This synergistic mechanism of action is designed to suppress B-cell proliferation and autoantibody production more effectively than single-pathway inhibitors. LUB006 is under clinical development for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS).

Other names

anti-IFNAR1-TACI antibody fusion proteinanti-IFNAR-1-TACI antibody fusion proteinanti-IFNAR 1-TACI antibody fusion proteinanti-IFNAR1-TACI fusion proteinanti-IFNAR-1-TACI fusion proteinanti-IFNAR 1-TACI fusion protein